Podcast

CGTs For HIV Suppression With Addimmune's Dr. Marcus Conant

Source: Cell & Gene
23_12_CGPodcast_1280x720_Ep75

On this episode of Cell & Gene: The Podcast, Addimmune CMO, Dr. Marcus Conant, shares the why behind cell and gene therapy to treat HIV, and explains the company's lead asset, AGT103-T, which is designed to provide broad protection using silencing RNA to inhibit binding/entry of the virus, halt replication, and prevent escape.

access the Podcast!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.

Subscribe to Cell & Gene X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Cell & Gene

Please tell us more about you so that we can customize our newsletters to your specific interests:

What topics interest you? (Check all that apply.)